FDA’s Gottlieb launches biosimilars action plan

19-07-2018

FDA’s Gottlieb launches biosimilars action plan

Ildo Frazao / iStockphoto.com

The US Food and Drug Administration (FDA) is not going to play regulatory ‘whack-a-mole’ with companies trying to delay or derail the entry of biosimilar competitors, according to Scott Gottlieb, commissioner of the FDA.


Food and Drug Administration, Scott Gottlieb, biosimilars, biosimilars action plan, FDA, biotech, regulatory, drug pricing

LSIPR